Arrowhead Pharmaceuticals, Inc. share price logo

Arrowhead Pharmaceuticals, Inc. Share Price

NASDAQ: ARWR

Mid Cap

$56.27

-0.40

(-0.71%)

as on

Arrowhead Pharmaceuticals, Inc. Stock Performance

as on March 25, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $55.01
    $56.87
    downward going graph

    2.24%

    Downside

    1.07%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $9.57
    $76.76
    downward going graph

    82.99%

    Downside

    36.41%

    Upside

    downward going graph

Arrowhead Pharmaceuticals, Inc. share price movements today

Previous Close
$56.67
Open
$56.05
Volume
1.0M
Day's Low - High
$55.01 - $56.87
52 Week Low - High
$9.57 - $76.76

Arrowhead Pharmaceuticals, Inc. Historical Returns

1 Month Return
-8.67 %
3 Month Return
-19.74 %
1 Year Return
+ 282.01 %
3 Year Return
+ 131.66 %
5 Year Return
-13.71 %

Arrowhead Pharmaceuticals, Inc. Stock Fundamentals & Key Indicators

Check Arrowhead Pharmaceuticals, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$7.9B

EPS (TTM)

-3.2391

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.10%

PE Ratio (TTM)

35.17

Industry PE ratio

7.867522123893806

PEG Ratio

-1.32

EBITDA

325.6M

Revenue (TTM)

1.1B

Profit Margin

18.54%

Return On Equity TTM

75.50%

Arrowhead Pharmaceuticals, Inc. Stock Valuation

Track how Arrowhead Pharmaceuticals, Inc. P/E has moved over time to understand its valuation trends.

Arrowhead Pharmaceuticals, Inc. in the last 5 years

  • Overview

  • Trends

Lowest (-72.52x)

March 31, 2021

Industry (7.87x)

March 25, 2026

Today (35.17x)

March 25, 2026

Highest (30.63x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: 35.17x

Arrowhead Pharmaceuticals, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Arrowhead Pharmaceuticals, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Arrowhead Pharmaceuticals, Inc. image
Arrowhead Pharmaceuticals, Inc.
BUY$7.9B-13.71%35.1718.54%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$40.7B127.78%131.618.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$114.6B111.25%29.4232.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$31.6BNA111.235.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$77.9B60.03%17.7631.41%

Stock Returns calculator for Arrowhead Pharmaceuticals, Inc. Stock including INR - Dollar returns

The Arrowhead Pharmaceuticals, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Arrowhead Pharmaceuticals, Inc. investment value today

Current value as on today

₹3,92,022

Returns

₹2,92,022

(+292.02%)

Returns from Arrowhead Pharmaceuticals, Inc. Stock

₹2,82,010 (+282.01%)

Dollar Returns*

₹10,013 (+10.01%)

Analyst Recommendation on Arrowhead Pharmaceuticals, Inc. Stock

Based on 20 analysts

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Based on 20 analysts, 75% of analysts recommend a 'BUY' rating for Arrowhead Pharmaceuticals, Inc.. Average target price of $81.36

Arrowhead Pharmaceuticals, Inc. Share Price Target

Get share price movements and forecasts by analysts on Arrowhead Pharmaceuticals, Inc..

What analysts predicted

30.84%UPSIDE

Target Price

$81.36

Current Price

$56.27

Analyzed by

20 Analysts

Target

$81.36

Arrowhead Pharmaceuticals, Inc. target price $81.36, a slight upside of 30.84% compared to current price of $56.27. According to 20 analysts rating.

Arrowhead Pharmaceuticals, Inc. Stock’s Investor Sentiment and Interest

Search interest for Arrowhead Pharmaceuticals, Inc. Stock has decreased by -44% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-44% versus previous 30 day period

Arrowhead Pharmaceuticals, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
16
3
-
-
23
2
542
27
256
264
Gross Profit
12
3
-4
-4
10
2
542
21
256
264
Operating Income
-108
-136
-126
-176
-162
-161
381
-165
44
40
EBITDA
-99
-129
-115
-164
-153
-148
397
-148
64
57
Interest Expense
5
5
7
5
14
21
21
24
21
22
Depreciation
3
4
4
4
5
5
6
6
6
6
Income Before Tax
-108
-138
-126
-173
-172
-175
369
-175
36
28
Income Tax Expense
2
-3
-1
-3
0
0
1
2
20
0
Net Income
-109
-132
-125
-170
-170
-173
370
-175
-23
30
Net Profit Margin
-681.36%
-3741.59%
0.00%
0.00%
-722.95%
-6923.40%
68.26%
-631.11%
-9.26%
11.67%

Arrowhead Pharmaceuticals, Inc. Annual Profit & Loss

All numbers in Millions USD

Sep 2016
Sep 2017
Sep 2018
Sep 2019
Sep 2020
Sep 2021
Sep 2022
Sep 2023
Sep 2024
Sep 2025
Total Revenue
0
31
16
168
87
138
243
240
3
829
Gross Profit
0
31
16
168
87
138
243
240
3
805
Operating Income
-81
-36
-55
61
-93
-149
-178
-205
-601
98
EBITDA
-76
-32
-51
65
-87
-132
-168
-175
-561
164
Interest Expense
265
415
1,048
6,957
9,190
6
5
18
32
89
Depreciation
-
4
4
4
5
8
10
12
18
23
Income Before Tax
-81
-34
-54
68
-84
-140
-172
-206
-612
51
Income Tax Expense
0
0
0
0
0
0
3
2
-2
21
Net Income
-81
-34
-54
67
-84
-140
-176
-205
-599
-1
Net Profit Margin
-51614.63%
-109.46%
-337.32%
40.27%
-96.09%
-101.85%
-72.56%
-85.27%
-16882.37%
-0.20%

Arrowhead Pharmaceuticals, Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-135
-126
-173
-173
-175
367
-178
16
28
Operating Cash Flow
-117
-92
-115
-137
-146
460
-154
20
13
Investing Cash Flow
64
-268
6
-222
76
-420
141
72
-23
Financing Cash Flow
0
430
50
389
20
92
-42
3
-14
Change in Cash
-52
69
-58
33
-48
131
-55
96
-24

Arrowhead Pharmaceuticals, Inc. Annual Cash Flow

All numbers in Millions USD

Sep 2017
Sep 2018
Sep 2019
Sep 2020
Sep 2021
Sep 2022
Sep 2023
Sep 2024
Sep 2025
Net Income
-34
-54
67
-84
-140
-176
-209
-609
30
Operating Cash Flow
-23
-47
173
-95
171
-136
-153
-462
179
Investing Cash Flow
-48
-7
-47
-240
-141
-5
-96
-420
-129
Financing Cash Flow
12
59
66
257
11
65
253
870
74
Change in Cash
-60
5
191
-78
40
-76
2
-8
123

Global Institutional Holdings in Arrowhead Pharmaceuticals, Inc.

Funds
Holdings
venBio Select Advisor LLC
7.78%
Geode Capital Management, LLC
2.33%
Deerfield Management Co
1.31%
Goldman Sachs Group Inc
1.53%
JPMorgan Chase & Co
1.11%
See all

Arrowhead Pharmaceuticals, Inc. News & Key Events

  • img

    Today's Timeline - 25 November

    Tue, 11:38 PM

    -

    Sarepta triggers a $200 million milestone payment to Arrowhead Pharmaceuticals as part of a licensing deal.

    Wed, 02:48 AM

    -

    Arrowhead Pharmaceuticals releases its 10-K report, showcasing improved financial performance and strategic initiatives in RNAi therapeutics.

Insights on Arrowhead Pharmaceuticals, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ARWR has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -175.24M → 30.81M (in $), with an average increase of 407.5% per quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ARWR has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, ARWR stock has moved up by 77.7%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 27.76M → 264.03M (in $), with an average increase of 46.0% per quarter

About Arrowhead Pharmaceuticals, Inc.

arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
OrganisationArrowhead Pharmaceuticals, Inc.
Headquarters177 East Colorado Boulevard, Pasadena, CA, United States, 91105
IndustryHealth Technology
CEODr. Christopher R. Anzalone Ph.D.
E-voting on sharesClick here to vote

Key Management of Arrowhead Pharmaceuticals, Inc.

Name

Title

Mr. Howard Lovy

Director of Communications

Dr. Mark Seefeld

Head of Toxicology & VP

Mr. Patrick O'Brien J.D., PharmD

COO & Secretary

Dr. Vincent Anzalone CFA

Head of Investor Relations & VP

Dr. James C. Hamilton M.D., MBA

Chief Medical Officer and Head of R&D

Dr. Mark M. Davis Ph.D.

Founder and Founder & Director of Insert Therapeutics Inc & Calando

Dr. Tao Pei Ph.D.

Chief Scientific Officer

Dr. Bruce D. Given M.D.

Chief Medical Scientist

Dr. Christopher R. Anzalone Ph.D.

Chairman, CEO & President

Mr. Daniel J. Apel

Chief Financial Officer

FAQs

What is Arrowhead Pharmaceuticals, Inc. share price today?

Arrowhead Pharmaceuticals, Inc. share price today is $56.27 as on at the close of the market. Arrowhead Pharmaceuticals, Inc. share today touched a day high of $56.87 and a low of $55.01.

What is the 52 week high and 52 week low for Arrowhead Pharmaceuticals, Inc. share?

Arrowhead Pharmaceuticals, Inc. share touched a 52 week high of $76.76 on and a 52 week low of $9.57 on . Arrowhead Pharmaceuticals, Inc. stock price today i.e. is closed at $56.27,which is 26.69% down from its 52 week high and 487.98% up from its 52 week low.

What is Arrowhead Pharmaceuticals, Inc.'s market capitalisation today?

Arrowhead Pharmaceuticals, Inc. market capitalisation is $0.01T as on .

How to invest in Arrowhead Pharmaceuticals, Inc. Stock (ARWR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Arrowhead Pharmaceuticals, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Arrowhead Pharmaceuticals, Inc. Shares that will get you 0.0267 shares as per Arrowhead Pharmaceuticals, Inc. share price of $56.27 per share as on March 25, 2026 at 1:29 am IST.

What is the minimum amount required to buy Arrowhead Pharmaceuticals, Inc. Stock (ARWR) from India?

Indian investors can start investing in Arrowhead Pharmaceuticals, Inc. (ARWR) shares with as little as ₹94.138 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹941.38 in Arrowhead Pharmaceuticals, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Arrowhead Pharmaceuticals, Inc. share’s latest price of $56.27 as on March 25, 2026 at 1:29 am IST, you will get 0.1777 shares of Arrowhead Pharmaceuticals, Inc.. Learn more about fractional shares .

What are the returns that Arrowhead Pharmaceuticals, Inc. has given to Indian investors in the last 5 years?

Arrowhead Pharmaceuticals, Inc. stock has given -13.71% share price returns and 28.4% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?